메뉴 건너뛰기




Volumn 61, Issue 7, 2007, Pages 1063-

Ranolazine - A nicely timed new medical therapy for stable angina

(1)  Jackson, Graham a  

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RANOLAZINE; TRIMETAZIDINE;

EID: 34250628123     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01457.x     Document Type: Editorial
Times cited : (1)

References (7)
  • 1
    • 34248383128 scopus 로고    scopus 로고
    • Stable and also unstable coronary disease - COURAGE and the importance of optimal medical therapy
    • Jackson G. Stable and also unstable coronary disease - COURAGE and the importance of optimal medical therapy. Int J Clin Pract 2007 61: 883.
    • (2007) Int J Clin Pract , vol.61 , pp. 883
    • Jackson, G.1
  • 2
    • 34247113737 scopus 로고    scopus 로고
    • Optimal medical therapy with or without PCI for stable coronary disease
    • Boden WE, O'Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 356: 1503 16.
    • (2007) N Engl J Med , vol.356 , pp. 1503-16
    • Boden, W.E.1    O'Rourke, R.A.2    Teo, K.K.3
  • 3
    • 33947606182 scopus 로고    scopus 로고
    • Five year follow-up of the Medicine, Angioplasty or Surgery Study (MASS II): A randomised controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease
    • Hueb W, Lopes NH, Gersh BJ et al. Five year follow-up of the Medicine, Angioplasty or Surgery Study (MASS II): a randomised controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007 115: 1082 89.
    • (2007) Circulation , vol.115 , pp. 1082-89
    • Hueb, W.1    Lopes, N.H.2    Gersh, B.J.3
  • 4
    • 0037247750 scopus 로고    scopus 로고
    • A metabolic approach to the management of ischemic heart disease: Clinical benefits with trimetazidine
    • Jackson G. A metabolic approach to the management of ischemic heart disease: clinical benefits with trimetazidine. Am J Cardiovasc Drugs 2003 3 (Suppl. 1 27 33.
    • (2003) Am J Cardiovasc Drugs , vol.3 , Issue.1 , pp. 27-33
    • Jackson, G.1
  • 5
    • 34247096461 scopus 로고    scopus 로고
    • Ranolazine: A novel agent that improves dysfunctional sodium channels
    • Pham DQ, Mehta M. Ranolazine: a novel agent that improves dysfunctional sodium channels. Int J Clin Pract 2007 61: 864 872.
    • (2007) Int J Clin Pract , vol.61 , pp. 864-872
    • Pham, D.Q.1    Mehta, M.2
  • 6
    • 34247526904 scopus 로고    scopus 로고
    • Effects of ranolazine on recurrent cardiovascular events in patients with non-ST elevation acute coronary syndromes: The MERLIN-TIMI 36 Randomised Trial
    • Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST elevation acute coronary syndromes: the MERLIN-TIMI 36 Randomised Trial. JAMA 2007 297: 1775 1783.
    • (2007) JAMA , vol.297 , pp. 1775-1783
    • Morrow, D.A.1    Scirica, B.M.2    Karwatowska-Prokopczuk, E.3
  • 7
    • 33847385380 scopus 로고    scopus 로고
    • Long-term safety of a novel antianginal agent in patients with severe chronic stable angina. the Ranolazine Open Label Experience (ROLE)
    • Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina. The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007 49: 1027 34.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1027-34
    • Koren, M.J.1    Crager, M.R.2    Sweeney, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.